DeepMed Research

University of Virginia

🇺🇸United States

Country: 🇺🇸United States

Ownership: Private

Established: 1819-01-01

Employees: 10K

Market Cap: -

Website: http://www.virginia.edu

Clinical Trials

Benefits of Continuous Glucose Monitoring With GEM Lifestyle Modification for Adults With Type 2 Diabetes

Not Applicable

Completed

Conditions: Diabetes Mellitus, Type 2

Interventions: Other: Routine Care
Behavioral: GEM lifestyle modification & continuous glucose monitoring

First Posted Date: 2017-07-05

Last Posted Date: 2021-02-26

Lead Sponsor: University of Virginia

Target Recruit Count: 24

Registration Number: NCT03207893

Locations: 🇺🇸
University of Virginia, Dept. of Psychiatry and Neurobehavioral Sciences, Charlottesville, Virginia, United States

Treating Type 2 Diabetes by Reducing Postprandial Glucose Elevations: A Paradigm Shift in Lifestyle Modification

Not Applicable

Completed

Conditions: Diabetes Mellitus, Type 2

Interventions: Behavioral: PPG training
Behavioral: Weight reduction training
Behavioral: continuous BG feedback
Behavioral: discrete BG feedback

First Posted Date: 2017-06-23

Last Posted Date: 2021-10-05

Lead Sponsor: University of Virginia

Target Recruit Count: 192

Registration Number: NCT03196895

Locations: 🇺🇸
Dept. of Psychiatry and Neurobehavioral Sciences, University of Virginia, Charlottesville, Virginia, United States

Evaluation of a Brief Tobacco Intervention in the US Military

Not Applicable

Completed

Conditions: Smoking, Hookah
Nicotine Dependence
Smoking, Cigar
Tobacco Smoking
Smoking, Pipe
Tobacco Use

Interventions: Behavioral: Standard smoking cessation intervention
Behavioral: BTI
Behavioral: Cigarette smoking military tailored pamphlet

First Posted Date: 2017-06-22

Last Posted Date: 2021-10-07

Lead Sponsor: University of Virginia

Target Recruit Count: 2999

Registration Number: NCT03196102

Locations: 🇺🇸
37th Training Group, Lackland Air Force Base, Texas, United States

The Effect of Cryotherapy on Cerebral Hemodynamics Within Healthy Subjects

Phase 1

Completed

Conditions: Cryotherapy Effect
Oxygen Deficiency

Interventions: Device: CryoHelmet

First Posted Date: 2017-06-14

Last Posted Date: 2018-08-02

Lead Sponsor: University of Virginia

Target Recruit Count: 34

Registration Number: NCT03185507

Locations: 🇺🇸
University of Virginia Memorial Gymnasium, Charlottesville, Virginia, United States

Human Milk and Infant Intestinal Microbiome Study

Not Applicable

Completed

Conditions: Breast Feeding
Human Microbiome

Interventions: Other: Intervention education
Other: Placebo Education

First Posted Date: 2017-06-08

Last Posted Date: 2018-12-21

Lead Sponsor: University of Virginia

Target Recruit Count: 6

Registration Number: NCT03181269

Locations: 🇺🇸
University of Virginia, Charlottesville, Virginia, United States

Prematurity-Related Ventilatory Control: Role in Respiratory Outcomes

Completed

Conditions: Infant, Premature

First Posted Date: 2017-06-02

Last Posted Date: 2022-11-02

Lead Sponsor: University of Virginia

Target Recruit Count: 739

Registration Number: NCT03174301

Locations: 🇺🇸
University of Virginia, Charlottesville, Virginia, United States

The Impact of Fitness and Mineralocorticoid Receptor Blockade on Vascular Dysfunction in Adults With Type 1 Diabetes

Not Applicable

Completed

Conditions: Type 1 Diabetes

Interventions: Drug: Spironolactone
Other: Exercise

First Posted Date: 2017-06-02

Last Posted Date: 2019-12-18

Lead Sponsor: University of Virginia

Target Recruit Count: 32

Registration Number: NCT03174288

Locations: 🇺🇸
University of Virginia, Charlottesville, Virginia, United States

Safety and Tolerability of Lactoferrin/FOS in Very Low Birth Weight Infants

Early Phase 1

Conditions: Tolerance
Safety Issues
Very Low Birth Weight Infant

Interventions: Dietary Supplement: Lactoferrin/FOS

First Posted Date: 2017-05-22

Last Posted Date: 2017-05-22

Lead Sponsor: University of Virginia

Target Recruit Count: 20

Registration Number: NCT03163212

Durvalumab in Different Combinations With Pralatrexate, Romidepsin and Oral 5-Azacitidine for Lymphoma

Phase 1

Conditions: Lymphoma, T-Cell

Interventions: Drug: Durvalumab
Drug: Romidepsin
Drug: Pralatrexate
Drug: 5-Azacitidine

First Posted Date: 2017-05-19

Last Posted Date: 2022-03-31

Lead Sponsor: University of Virginia

Target Recruit Count: 148

Registration Number: NCT03161223

Locations: 🇺🇸
University of Virginia, Charlottesville, Virginia, United States

Cultural Acceptability and Feasibility of HPV Cervical Self Collection Aided by Lay Navigators

Not Applicable

Completed

Conditions: Human Papilloma Virus

Interventions: Device: Viba collection brush

First Posted Date: 2017-05-04

Last Posted Date: 2022-09-16

Lead Sponsor: University of Virginia

Target Recruit Count: 100

Registration Number: NCT03139669

© Copyright 2025. All Rights Reserved by MedPath

Home Terms & Conditions Privacy Policy